BofA analyst Travis Steed lowered the firm’s price target on Beta Bionics (BBNX) to $11 from $23 and keeps a Neutral rating on the shares. After having hosted 34 medtech companies last week in Las Vegas, the firm updated several price targets for “the new reality of medtech valuations” in a year of few product cycles, ACA and utilization worries, inflation kicking up post-war, and “data centers over healthcare,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics Earnings Call Highlights Growth And Risks
- Beta Bionics price target lowered to $20 from $22 at Stifel
- Beta Bionics price target lowered to $20 from $32 at Piper Sandler
- Closing Bell Movers: Capital One, Interactive Brokers slip after results
- Beta Bionics reports Q1 EPS (49c), consensus (45c)